Cargando…

Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice

Tau tubulin kinase-1 (TTBK1), a neuron-specific tau kinase, is highly expressed in the entorhinal cortex and hippocampal regions, where early tau pathology evolves in Alzheimer’s disease (AD). The protein expression level of TTBK1 is elevated in the cortex brain tissues with AD patients compared to...

Descripción completa

Detalles Bibliográficos
Autores principales: Yukawa, Kayo, Yamamoto-Mcguire, Satomi, Cafaro, Louis, Hong, Christine, Kamme, Fredrik, Ikezu, Tsuneya, Ikezu, Seiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585748/
https://www.ncbi.nlm.nih.gov/pubmed/37853497
http://dx.doi.org/10.1186/s40478-023-01661-3
_version_ 1785123010142797824
author Yukawa, Kayo
Yamamoto-Mcguire, Satomi
Cafaro, Louis
Hong, Christine
Kamme, Fredrik
Ikezu, Tsuneya
Ikezu, Seiko
author_facet Yukawa, Kayo
Yamamoto-Mcguire, Satomi
Cafaro, Louis
Hong, Christine
Kamme, Fredrik
Ikezu, Tsuneya
Ikezu, Seiko
author_sort Yukawa, Kayo
collection PubMed
description Tau tubulin kinase-1 (TTBK1), a neuron-specific tau kinase, is highly expressed in the entorhinal cortex and hippocampal regions, where early tau pathology evolves in Alzheimer’s disease (AD). The protein expression level of TTBK1 is elevated in the cortex brain tissues with AD patients compared to the control subjects. We therefore hypothesized that antisense oligonucleotide (ASO) based targeting Ttbk1 could prevent the accumulation of phosphorylated tau, thereby delaying the development of tau pathology in AD. Here we show that in vivo administration of ASO targeting mouse Ttbk1 (ASO-Ttbk1) specifically suppressed the expression of Ttbk1 without affecting Ttbk2 expression in the temporal cortex of PS19 tau transgenic mice. Central administration of ASO-Ttbk1 in PS19 mice significantly reduced the expression level of representative phosphor-tau epitopes relevant to AD at 8 weeks post-dose, including pT231, pT181, and pS396 in the sarkosyl soluble and insoluble fractions isolated from hippocampal tissues as determined by ELISA and pS422 in soluble fractions as determined by western blotting. Immunofluorescence demonstrated that ASO-Ttbk1 significantly reduced pS422 phosphorylated tau intensity in mossy fibers region of the dentate gyrus in PS19 mice. RNA-sequence analysis of the temporal cortex tissue revealed significant enrichment of interferon-gamma and complement pathways and increased expression of antigen presenting molecules (Cd86, Cd74, and H2-Aa) in PS19 mice treated with ASO-Ttbk1, suggesting its potential effect on microglial phenotype although neurotoxic effect was absent. These data suggest that TTBK1 is an attractive therapeutic target to suppress TTBK1 without compromising TTBK2 expression and pathological tau phosphorylation in the early stages of AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01661-3.
format Online
Article
Text
id pubmed-10585748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105857482023-10-20 Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice Yukawa, Kayo Yamamoto-Mcguire, Satomi Cafaro, Louis Hong, Christine Kamme, Fredrik Ikezu, Tsuneya Ikezu, Seiko Acta Neuropathol Commun Research Tau tubulin kinase-1 (TTBK1), a neuron-specific tau kinase, is highly expressed in the entorhinal cortex and hippocampal regions, where early tau pathology evolves in Alzheimer’s disease (AD). The protein expression level of TTBK1 is elevated in the cortex brain tissues with AD patients compared to the control subjects. We therefore hypothesized that antisense oligonucleotide (ASO) based targeting Ttbk1 could prevent the accumulation of phosphorylated tau, thereby delaying the development of tau pathology in AD. Here we show that in vivo administration of ASO targeting mouse Ttbk1 (ASO-Ttbk1) specifically suppressed the expression of Ttbk1 without affecting Ttbk2 expression in the temporal cortex of PS19 tau transgenic mice. Central administration of ASO-Ttbk1 in PS19 mice significantly reduced the expression level of representative phosphor-tau epitopes relevant to AD at 8 weeks post-dose, including pT231, pT181, and pS396 in the sarkosyl soluble and insoluble fractions isolated from hippocampal tissues as determined by ELISA and pS422 in soluble fractions as determined by western blotting. Immunofluorescence demonstrated that ASO-Ttbk1 significantly reduced pS422 phosphorylated tau intensity in mossy fibers region of the dentate gyrus in PS19 mice. RNA-sequence analysis of the temporal cortex tissue revealed significant enrichment of interferon-gamma and complement pathways and increased expression of antigen presenting molecules (Cd86, Cd74, and H2-Aa) in PS19 mice treated with ASO-Ttbk1, suggesting its potential effect on microglial phenotype although neurotoxic effect was absent. These data suggest that TTBK1 is an attractive therapeutic target to suppress TTBK1 without compromising TTBK2 expression and pathological tau phosphorylation in the early stages of AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40478-023-01661-3. BioMed Central 2023-10-19 /pmc/articles/PMC10585748/ /pubmed/37853497 http://dx.doi.org/10.1186/s40478-023-01661-3 Text en © This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Yukawa, Kayo
Yamamoto-Mcguire, Satomi
Cafaro, Louis
Hong, Christine
Kamme, Fredrik
Ikezu, Tsuneya
Ikezu, Seiko
Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title_full Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title_fullStr Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title_full_unstemmed Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title_short Antisense oligonucleotide-based targeting of Tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in PS19 tauopathy mice
title_sort antisense oligonucleotide-based targeting of tau-tubulin kinase 1 prevents hippocampal accumulation of phosphorylated tau in ps19 tauopathy mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585748/
https://www.ncbi.nlm.nih.gov/pubmed/37853497
http://dx.doi.org/10.1186/s40478-023-01661-3
work_keys_str_mv AT yukawakayo antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT yamamotomcguiresatomi antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT cafarolouis antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT hongchristine antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT kammefredrik antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT ikezutsuneya antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice
AT ikezuseiko antisenseoligonucleotidebasedtargetingoftautubulinkinase1preventshippocampalaccumulationofphosphorylatedtauinps19tauopathymice